You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
華領醫藥(02552.HK)完成Dorzagliatin的III期單藥試驗
格隆匯 06-18 16:36

格隆匯6月18日丨華領醫藥(02552.HK)公告,公司於2020年6月18日宣佈Dorzagliatin(HMS5552)單藥治療III期註冊臨牀研究(SEED,也稱HMM0301)的52周核心資料,分析結果表明,dorzagliatin具有長期穩定療效和安全性。

這項註冊臨牀關鍵性III期試驗在中國未用藥2型糖尿病患者中開展,用以評估dorzagliatin的療效和安全性。2019年11月,公司宣佈SEED試驗達到主要療效和安全性終點。在52周試驗期間,dorzagliatin也改善了患者的HOMA2-β和胰島素抵抗指標。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account